MedPath

Endoscopic Surgery or Radiation Therapy in Treating Patients With Stage 0, Stage I, or Stage II Laryngeal Cancer of the Glottis

Phase 2
Completed
Conditions
Head and Neck Cancer
Registration Number
NCT00334997
Lead Sponsor
University College London Hospitals
Brief Summary

RATIONALE: Endoscopic surgery is a less invasive type of surgery for laryngeal cancer and may have fewer side effects and improve recovery. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether endoscopic surgery is more effective than radiation therapy in treating laryngeal cancer of the glottis.

PURPOSE: This randomized phase II trial is studying endoscopic surgery to see how well it works compared with radiation therapy in treating patients with stage 0, stage I, or stage II laryngeal cancer of the glottis.

Detailed Description

OBJECTIVES:

* Determine the feasibility of conducting a large phase III randomized study in the future, comparing radiotherapy vs endoscopic excision in patients with stage 0-II laryngeal cancer of the glottis.

* Determine patient acceptability of the proposed trial design.

* Compare the effect of using dedicated head and neck research nurses vs general nurses on patient recruitment.

* Refine outcome measures, including voice analysis and quality of life.

OUTLINE: This is a randomized, controlled, multicenter, pilot study. Patients are stratified according to participating center and T stage (Tis or T1 vs T2a). Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients undergo endoscopic excision via CO_2 laser or cold steel.

* Arm II: Patients undergo radiotherapy once daily, 5 days a week, for 3-4 weeks. Patients undergo vocal analysis at baseline and at 6 months and 1 and 2 years after randomization.

Quality of life is assessed at baseline, at 1 year, and then annually for 5 years.

After completion of study treatment, patients are followed periodically for up to 5 years.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Feasibility
Patient acceptability
Secondary Outcome Measures
NameTimeMethod
Voice analysis
Quality of life
Economic assessment

Trial Locations

Locations (6)

Southmead Hospital

🇬🇧

Bristol, England, United Kingdom

Aintree University Hospital

🇬🇧

Liverpool, England, United Kingdom

Clatterbridge Centre for Oncology

🇬🇧

Merseyside, England, United Kingdom

James Cook University Hospital

🇬🇧

Middlesbrough, England, United Kingdom

Norfolk and Norwich University Hospital

🇬🇧

Norwich, England, United Kingdom

Royal Infirmary - Castle

🇬🇧

Glasgow, Scotland, United Kingdom

Southmead Hospital
🇬🇧Bristol, England, United Kingdom

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.